{"id":262231,"date":"2026-06-02T13:30:00","date_gmt":"2026-06-02T17:30:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/06\/02\/nanodetection-technology-and-oligomerix-announce-exclusive-global-licensing-agreement-for-breakthrough-neurodegenerative-diagnostic-antibodies\/"},"modified":"2026-06-02T14:00:25","modified_gmt":"2026-06-02T18:00:25","slug":"nanodetection-technology-and-oligomerix-announce-exclusive-global-licensing-agreement-for-breakthrough-neurodegenerative-diagnostic-antibodies","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/06\/02\/nanodetection-technology-and-oligomerix-announce-exclusive-global-licensing-agreement-for-breakthrough-neurodegenerative-diagnostic-antibodies\/","title":{"rendered":"NanoDetection Technology\u2122 and Oligomerix\u2122 Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies"},"content":{"rendered":"

NanoDetection Technology\u2122 and Oligomerix\u2122 Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies<\/a><\/p>\n

https:\/\/www.businesswire.com\/news\/home\/20260602591343\/en\/NanoDetection-Technology-and-Oligomerix-Announce-Exclusive-Global-Licensing-Agreement-for-Breakthrough-Neurodegenerative-Diagnostic-Antibodies<\/a><\/p>\n

Publish Date: 2026-06-02 13:30:00<\/a><\/p>\n

Source Domain: www.businesswire.com<\/a><\/p>\n

FRANKLIN, Ohio & BRONX, N.Y.–(BUSINESS WIRE)–<\/span>NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix retains rights to therapeutic applications of the antibody panel.<\/p>\n

\nQuantifying Protein State Transitions<\/span><\/p>\n

\nThe licensed antibody portfolio represents a significant advancement in the characterization of Alzheimer\u2019s disease and other Tau-related pathologies. These highly specialized reagents enable differentiation among distinct Tau species, including cleavage-specific and conformationally altered forms located within the protein filament core.<\/p>\n

\nThis degree of specificity provides a foundation for distinguishing Alzheimer\u2019s disease-associated Tau pathology from related neurodegenerative disorders, including Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), while also enabling quantitative characterization of disease-associated protein aggregation.<\/p>\n

\nNanoDetection has integrated these antibodies into its proprietary TRACE-Tau\u2122 platform, establishing a quantitative framework for monitoring protein-state transitions across the Alzheimer\u2019s disease pathological continuum. The resulting assays are being developed for deployment on NanoDetection\u2019s proprietary Luminorix\u2122 instrument system using the company\u2019s Accuglo\u2122 chemiluminescent assay architecture.<\/p>\n

\nHuman Sample Characterization and Translational Validation<\/span><\/p>\n

\nData generated from analyses of multiple Alzheimer\u2019s disease patient samples have demonstrated detection and characterization of aggregated Tau species across a variety of human sample types,…<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

NanoDetection Technology\u2122 and Oligomerix\u2122 Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies https:\/\/www.businesswire.com\/news\/home\/20260602591343\/en\/NanoDetection-Technology-and-Oligomerix-Announce-Exclusive-Global-Licensing-Agreement-for-Breakthrough-Neurodegenerative-Diagnostic-Antibodies…<\/p>\n","protected":false},"author":1,"featured_media":262232,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/mms.businesswire.com\/media\/20260602591343\/en\/2822109\/22\/NanoDetection-Technology-Logo-Small.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-262231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/262231"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=262231"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/262231\/revisions"}],"predecessor-version":[{"id":262233,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/262231\/revisions\/262233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/262232"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=262231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=262231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=262231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}